Table 1.

Patient characteristics in the training and validation cohorts

	Training cohort (n = 122)	Validation cohort (n = 53)	P
Age (years)			0.727
< 60	81	37
≥ 60	41	16
Menopause status			0.858
No	35	16
Yes	87	37
BMI	24.2009 ± 3.4156	24.9519 ± 3.5096	0.803
FIGO			0.186
IA	69	25
IB	13	9
II	22	6
III–IV	18	13
Pathological type			0.896
Endometrioid adenocarcinoma	100	43
Non-endometrioid adenocarcinoma	22	10
Differentiation			0.309
Low grade	29	17
Middle grade	50	23
High grade	43	13
Tumor size			0.507
< 2 cm	18	10
≥ 2 cm	104	43
Lymph node metastasis(LNM)			0.063
Non-metastasis	113	44
Metastasis	9	9
Lymphovascular space invasion (LVSI)			0.150
Non-LVSI	109	43
LVSI	13	10
Depth of myometrial invasion (DMI)			0.579
< 1/2	91	37
≥ 1/2	31	16
CA125			0.678
< 35 U/ml	100	42
≥ 35 U/ml	22	11
Rad-score	0.02364	− 0.05443	0.337
Recurrence			0.638
Yes	26	13
No	96	40
Death			0.615
Yes	15	8
No	107	45